

Teradyne Reports Fourth Quarter and Fiscal Year 2023 Results

Tuesday, 30 January 2024 17:15

TERADYNE

Teradyne, Inc.

Topic:

Earnings

Share this Article







- Revenue of \$671 million in Q4'23, down 8% from Q4'22
- Revenue of \$2,676 million in FY 2023, down 15% from FY 2022
- Record Robotics revenue in Q4'23, up 50% from Q3'23 and 17% from Q4'22

								\mathbf{FY}	
	Q4'23	Q4'22		Q3'23		FY 2023		2022	
Revenue (mil)	\$ 671	\$	732	\$	704	\$	2,676	\$3,155	
GAAP EPS	\$ 0.72	\$	1.04	\$	0.78	\$	2.73	\$ 4.22	
Non-GAAP EPS	\$ 0.79	\$	0.92	\$	0.80	\$	2.93	\$ 4.25	

NORTH READING, MA / ACCESSWIRE / January 30, 2024 / Teradyne, Inc. (NASDAQ:TER) reported revenue of \$671 million for the fourth quarter of 2023 of which \$431 million was in Semiconductor Test, \$86 million in System Test, \$25 million in Wireless Test and \$129 million in Robotics. GAAP net income for the fourth quarter was \$117 million or \$0.72 per diluted share. On a non-GAAP basis, Teradyne's net income in the fourth quarter was \$127 million, or \$0.79 per diluted share, which excluded pension actuarial losses, acquired intangible asset amortization, restructuring and other charges, and included the related tax impact on non-GAAP adjustments.

"We closed out 2023 with Q4 revenue and profit in line with our guidance as strong demand for memory test systems and 50% quarterly growth of Robotics revenue offset weakening demand for System-on-a-Chip (SOC) test systems," said Teradyne CEO Greg Smith. "Looking into the new year, we expect low tester utilization will impact demand in the first half of the year but anticipate the full year Semiconductor test demand to incrementally improve from 2023. In Robotics, after expected seasonal weakness in Q1, we project consistent quarterly growth powered by new products, new applications and improvements in our global distribution channels."

Guidance for the first quarter of 2024 is revenue of \$540 million to \$590 million, with GAAP net income of \$0.19 to \$0.35 per diluted share and non-GAAP net income of \$0.22 to \$0.38 per diluted share. Non-GAAP guidance excludes acquired intangible asset amortization and includes the related tax impact on non-GAAP adjustments.

Webcast



www.teradyne.com/investors [pr.report].

Non-GAAP Results

In addition to disclosing results that are determined in accordance with GAAP, Teradyne also discloses non-GAAP results of operations that exclude certain income items and charges. These results are provided as a complement to results provided in accordance with GAAP. Non-GAAP income from operations and non-GAAP net income exclude acquired intangible assets amortization, restructuring and other, pension actuarial gains and losses, stock compensation modification expense, discrete income tax adjustments, and includes the related tax impact on non-GAAP adjustments. GAAP requires that these items be included in determining income from operations and net income. Non-GAAP income from operations, non-GAAP net income, non-GAAP income from operations as a percentage of revenue, non-GAAP net income as a percentage of revenue, and non-GAAP net income per share are non-GAAP performance measures presented to provide meaningful supplemental information regarding Teradyne's baseline performance before gains, losses or other charges that may not be indicative of Teradyne's current core business or future outlook. These non-GAAP performance measures are used to make operational decisions, to determine employee compensation, to forecast future operational results, and for comparison with Teradyne's business plan, historical operating results and the operating results of Teradyne's competitors. Non-GAAP diluted shares include the impact of Teradyne's call option on its shares. Management believes each of these non-GAAP performance measures provides useful supplemental information for investors, allowing greater transparency to the information used by management in its operational decision making and in the review of Teradyne's financial and operational performance, as well as facilitating meaningful comparisons of Teradyne's results in the current period compared with those in prior and future periods. A reconciliation of each available GAAP to non-GAAP financial measure discussed in this press release is contained in the attached exhibits and on the Teradyne website at http://www.teradyne.com by clicking on "Investor Relations" and then selecting "Financials" and the "GAAP to Non-GAAP Reconciliation" link. The non-GAAP performance measures discussed in this press release may not be comparable to similarly titled measures used by other companies. The presentation of non-GAAP measures is not meant to be considered in isolation, as a substitute for, or superior to, financial measures or information provided in accordance with GAAP.

About Teradyne

Teradyne (<u>NASDAQ:TER</u>) test technology helps bring high-quality innovations such as smart devices, life-saving medical equipment and data storage systems to market, faster. Its advanced test solutions for semiconductors, electronic systems, wireless devices and more ensure that products perform as they were designed. Its robotics offerings include collaborative and mobile robots that help manufacturers of all sizes increase productivity, improve safety, and lower costs. In 2023, Teradyne had revenue of \$2.7 billion and today employs over 6,500 people worldwide. For more information, visit <u>teradyne.com</u>. Teradyne [®] is a registered trademark of Teradyne, Inc., in the U.S. and other countries.

Safe Harbor Statement

This release contains forward-looking statements including statements regarding Teradyne's future business prospects, financial performance or position and results of operations. You can identify forward-looking statements by their use of forward-looking words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "goal" or other comparable terms. Forward-looking statements in this press release address various matters, including statements regarding Teradyne's financial guidance. Investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements due to known and unknown risks, uncertainties, assumptions, and other factors. Such factors include, but are not limited to, macroeconomic factors and slowdowns or downturns in economic conditions generally and in the markets in which Teradyne operates; decreased or delayed product demand from one or more significant customers; a slowdown or inability in the development, delivery and acceptance of new products; the ability to grow the Robotics business; the impact of increased research and development spending; the impact of epidemics or pandemics such as COVID-19; the impact of a supply shortage on our supply chain and contract manufacturers; the consummation and success of any mergers or acquisitions; unexpected cash needs; the business judgment of the board of directors that a declaration of a dividend or the repurchase of common stock is not in Teradyne's best interests; changes to U.S. or global tax regulations or guidance; the impact of any tariffs or export controls imposed by the U.S. or China; the impact of U.S. Department of Commerce or other government agency regulations relating to Huawei, HiSilicon and other customers or potential customers; the impact of U.S. Department Commerce export control regulations for certain U.S. products and technology sold to military end users or for military end-use in China; the impact of the Israel-Hamas conflict; the impact of regulations published by the U.S. Department of Commerce relating to semiconductors and semiconductor manufacturing equipment destined for certain end uses in China. The risks included above are not exhaustive. For a more detailed description of the risk factors associated with Teradyne, please refer to Teradyne's Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and Quarterly Report on Form 10-Q for the fiscal guarter ended October 1, 2023. Many of these factors are macroeconomic in nature and are, therefore, beyond Teradyne's control. We caution readers not to place undue reliance on any forward-looking statements included in this press release which speak only as to the date of this press release. Teradyne specifically disclaims any obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.

TERADYNE, INC. REPORT FOR FOURTH FISCAL QUARTER OF 2023

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Quarter Ended

Twelve Months Ended





Net revenues	\$ 67/0,600	\$	7/03,732	\$	731,836	\$	2,676,298	\$	3,155,045
Cost of revenues (exclusive of acquired intangible assets									
amortization shown separately below) (1)	 291,055		305,441		311,387		1,139,550		1,287,894
Gross profit	379,545		398,291		420,449		1,536,748		1,867,151
Operating expenses:									
Selling and administrative (2)	142,336		138,330		142,752		577,315		558,103
Engineering and development	102,207		104,413		108,810		418,089		440,591
Acquired intangible assets amortization	4,651		4,720		4,670		18,999		19,333
Restructuring and other (3)	6,027		6,856		(2,369))	21,277		17,185
Operating expenses	255,221		254,319		253,863		1,035,680		1,035,212
Income from operations	124,324		143,972		166,586		501,068		831,939
Interest and other (income) expense (4)	(15,482))	(308)		(28,651))	(24,504)		(8,446)
Income before income taxes	139,806		144,280		195,237		525,572		840,385
Income tax provision	22,752		16,164		22,936		76,820		124,884
Net income	\$ 117,054	\$	128,116	\$	172,301	\$	448,752	\$	715,501
Net income per common share:									
Basic	\$ 0.77	\$	0.83	\$	1.11	\$	2.91	\$	4.52
Diluted	\$ 0.72	\$	0.78	\$	1.04	\$	2.73	\$	4.22
Weighted average common shares - basic	152,812		153,762		155,762		154,310		158,434
Weighted average common shares - diluted (5)	162,106		164,050		165,468		164,304		169,734
Cash dividend declared per common share	\$ 0.11	\$	0.11	\$	0.11	\$	0.44	\$	0.44
(1) Cost of revenues includes:									
	(Qua	rter Ended	l			Twelve Mo	nth	s Ended

				5 Lilucu						
	December				D	ecember	Ι	December	D	ecember
		31, 2023		ctober 1,		31,		31,		31,
				2023		2022		2023		2022
Provision for excess and obsolete inventory	\$	5,289	\$	11,728	\$	11,787	\$	28,358	\$	31,452
Sale of previously written down inventory		(1,115)		(1,198)		(828))	(5,161)		(1,808)
	\$	4,174	\$	10,530	\$	10,959	\$	23,197	\$	29,644
							_			

(2) For the twelve months ended December 31, 2023, selling and administrative expenses included an equity charge of \$5.9 million for the modification of Teradyne's retired CEO's outstanding equity awards in connection with his February 1, 2023 retirement.

(3) Restructuring and other consists of:

		(d	Twelve Months Ended			
	D	ecember		December	December	December	
	31,		October 1,	31,	31,	31,	
		2023	2023	2022	2022 2023		
Acquisition and divestiture related expenses	\$	3,132	\$ -	\$ -	\$ 3,132	\$ -	
Employee severance		2,892	4,658	775	14,727	2,924	
Contract termination		-	1,511	-	1,511	-	
Litigation settlement		-	-	-	-	14,700	
Gain on sale of asset		-	-	(3,410)	-	(3,410)	
Other		3	687	266	1,907	2,971	
	\$	6,027	\$ 6,856	\$ (2,369)	\$ 21,277	\$ 17,185	

(4) Interest and other (income) expense includes:

		(Quai	rter Ended	l		Twelve Months Ended		
	D	December			De	ecember	December	D	ecember
		31, 2023		ctober 1,	31,		31,		31,
				2023		2023	2022		2023
Pension actuarial losses (gains)	\$	2,575	\$	72	\$	(25,592)	\$ 2,703	\$	(25,584)
Gain on foreign exchange option		(7,464)		-		-	(7,464))	-



been included in diluted shares. For the quarters ended December 31, 2023, October 1, 2023 and December 31, 2022, diluted shares also included 8.6 million, 9.2 million and 7.9 million shares, respectively, from the convertible note hedge transaction. For the twelve months ended December 31, 2023 and December 31, 2022, diluted shares included 8.9 million and 8.8 million shares, respectively, from the convertible note hedge transaction.

CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands)

	December 31, 2023	December 31, 2022
Assets		
Cash and cash equivalents	\$ 757,571	\$ 854,773
Marketable securities	62,154	39,612
Accounts receivable, net	422,124	491,145
Inventories, net	309,974	325,019
Prepayments	548,970	532,962
Other current assets	37,992	14,404
Current assets held for sale	23,250	-
Total current assets	2,162,035	2,257,915
Property, plant and equipment, net	445,492	418,683
Operating lease right-of-use assets, net	73,417	73,734
Marketable securities	117,434	110,777
Deferred tax assets	175,775	142,784
Retirement plans assets	11,504	11,761
Other assets	38,580	28,925
Acquired intangible assets, net	35,404	53,478
Goodwill	415,652	403,195
Assets held for sale	11,531	-
Total assets	\$ 3,486,824	\$ 3,501,252
Liabilities		
Accounts payable	\$ 180,131	\$ 139,722
Accrued employees' compensation and withholdings	191,750	212,266
Deferred revenue and customer advances	99,804	148,285
Other accrued liabilities	114,712	112,271
Operating lease liabilities	17,522	18,594
Income taxes payable	48,653	65,010
Current debt	-	50,115
Current liabilities held for sale	7,379	
Total current liabilities	659,951	746,263
Retirement plans liabilities	132,090	116,005
Long-term deferred revenue and customer advances	37,282	45,131
Long-term other accrued liabilities	19,998	15,981
Deferred tax liabilities	183	3,267
Long-term operating lease liabilities	65,092	64,176
Long-term income taxes payable	44,331	59,135
Liabilities held for sale	2,000	
Total liabilities	960,927	1,049,958
Shareholders' equity	2,525,897	2,451,294
Total liabilities and shareholders' equity	\$ 3,486,824	\$ 3,501,252

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands)

	Quarter Ended					Twelve Months Ended			
	December 31, 2023		De	cember 31, 2022	Dec	cember 31, 2023	De	cember 31, 2022	
Cash flows from operating activities:									
Net income	\$	117,054	\$	172,301	\$	448,752	\$	715,501	
Adjustments to reconcile net income to net cash provided by operating									
activities:									
Depreciation		23,260		22,861		92,118		90,763	



Common staces on investments					
Retirement plans actuarial losses (gains) 2,575 (25,592) 2,703 (25,584) Gains on sale of asest (3,410) 1,610 9,635 2,336 Changes in operating assets and liabilities W 1,026 70,977 50,628 Inventories (1,086) 46,380 70,977 50,628 Inventories (1,086) 41,982 43,101 (140,705) Prepayments and other assets 20,881 46,882 43,101 (140,705) Accounts payable and other liabilities 42,783 11,911 46,782 60,507 Perpayments and contributions 1,774 (1,201) (5,492) (5,116) Retirement plans contributions 1,774 (1,201) (5,492) (5,116) Retirement plans contributions 1,774 (1,201) (5,493) (5,116) Retirement plans contributions 1,774 (1,201) (5,493) (5,116) Retirement plans contributions 1,243 1,340 (5,494) (1,624) Purchase of property plant and equipment (4,433)	Deferred taxes	(13,010)	(10,320)	(37,042)	(38,093)
Gains on sale of asset (3,40) (3,40) (3,40) (3,40) (3,40) (3,40) (3,40) (3,40) (3,40) (3,50) (2,53) (3,50)	(Gains) losses on investments	(11,756)	(1,451)	(14,915)	9,985
Other (81) 1,621 (95) 2,33 Changes in operating assets and liabilities 44,786 46,380 70,977 80,808 Accounts receivable 44,786 (11,992) 5,327 (80,809) Prepayments and other assets 20,881 (46,382) 43,101 (140,713) Accounts payable and other liabilities 42,783 11,911 46,782 (60,507) Deferred revenue and customer advances (7,693) 337 572,101 (62,33) Retirement plans contributions 13,762 15,362 26,921 (29,344) Net cash provided by operating activities 248,780 183,402 585,211 577,923 Net cash provided by operating activities 448,780 183,402 585,231 577,923 Post cash provided by operating activities 448,780 183,402 585,231 577,923 Purchases of property, plant and equipment (44,352) (35,572) 1616,349 222,411 Purchases of property, plant and equipment (44,362) 40,494 85,042 222,411	Retirement plans actuarial losses (gains)	2,575	(25,592)	2,703	(25,584)
Changes in operating assets and liabilities 40,786 46,380 70,977 50,628 Inventories (1,068) (11,992) 5,327 (80,809) Prepayments and other assets 20,881 (46,382) (43,101) (140,713) Accounts payable and other liabilities 42,783 11,911 46,782 (60,507) Deferred revenue and customer advances (7,693) (337) (57,210) (62,331) Retirement plans contributions (15,762) 13,302 (57,210) (52,834) Net eash provided by operating activities 248,780 183,402 585,231 577,923 Cash flows from investing activities 248,780 183,402 585,231 577,923 Purchases of property, plant and equipment (44,336) (34,57) (159,642) (163,349) Purchases of marketable securities (24,138) 8,858 61,401 268,058 Proceeds from sales of marketable securities 13,595 40,849 85,042 222,941 Issuance of convertible loan 5,505 40,849 8,542 222,941	Gains on sale of asset	-	(3,410)	-	(3,410)
Necounts receivable 40,786 46,380 70,977 50,628 Inventories (1,068 (11,982 5,327 68,0899 Prepayments and other assets 20,881 (46,382 43,101 (140,750) Accounts payable and other liabilities 42,783 11911 46,782 (65,077 Deferred revenue and customer advances (7,693 11911 46,782 (51,116) Deferred revenue and customer advances (1,794 11,219 5,492 5,116 Income taxes 15,762 15,36 62,921 62,833 Net cash provided by operating activities 248,780 183,402 585,231 579,238 Purchases of property, plant and equipment (44,336 34,577 (159,642 163,499 Purchases of marketable securities (24,120 20,234 161,906 287,499 Purchases of marketable securities (44,348 8,588 61,401 268,058 Proceeds from sales of marketable securities (44,348 8,588 61,401 268,058 Proceeds from sales of marketable securities (44,348 8,588 61,401 268,058 Proceeds from sales of marketable securities (44,369 40,494 40,494 40,494 40,494 Purchases of convertible loan (44,336 40,494 40,494 40,494 40,494 40,494 40,494 Proceeds from sales of marketable securities (44,368 40,494 40	Other	(811)	1,621	(955)	2,353
Inventories (1,068) (11,992) 5,327 (80,809) Prepayments and other assets 20,881 (46,382) (43,101) (140,713) Accounts payable and other liabilities 42,783 11,911 46,782 (60,507) Deferred revenue and customer advances (7,993) (33,7) (57,210) (62,33) Retirement plans contributions (1,794) (1,219) (5,492) (5,110) Income taxes 15,762 1,330 26,921) 79,720 Net cash provided by operating activities 24,878 18,3402 585,231 57,923 Post cash from investing activities (44,336) (34,577) (159,642) (29,834) Purchases of property, plant and equipment (44,336) (34,577) (159,642) (287,499) Purchases of marketable securities (24,120) (20,234) (1619,06) (287,499) Proceeds from maturities of marketable securities 13,595 4,849 85,042 222,941 Issuance of convertible loan (5,000) 1,600 1,600 1,600 1,600	Changes in operating assets and liabilities				
Prepayments and other assets 20,881 (46,382) (43,101) (140,713) Accounts payable and other liabilities 42,783 11,911 46,782 (60,507) Deferred revenue and customer advances (7,693) (337) (57,210) (62,331) Retirement plans contributions (1,794) (1,210) (5,492) (5,116) Income taxes 15,562 1,536 (26,921) (29,834) Net cash provided by operating activities 24,878 183,402 585,231 577,923 Cash flows from investing activities (24,338) (34,577) (159,642) (163,494) Purchases of marketable securities (24,120) (20,234) (161,906) (287,499) Proceeds from sales of marketable securities 24,438 8,888 61,401 268,058 Proceeds from sales of marketable securities 13,595 40,849 85,042 222,941 Issuance of convertible loan (30,22) 1,600 1,600 1,600 Proceeds from sale of asset (80,40) 1,000 1,700 3,415	Accounts receivable	40,786	46,380	70,977	50,628
Accounts payable and other liabilities 42,783 11,911 46,782 (60,507) Deferred revenue and customer advances (7,693) (337) (57,210) (62,33) Retirement plans contributions (1,794) (1,219) (5,492) (5,116) Income taxes 15,5762 1,536 (20,21) (29,834) Net cash provided by operating activities 248,780 183,402 585,21 577,221 Purchases of property, plant and equipment (44,336) (34,577) (159,642) (163,249) Purchases of marketable securities (24,120) (20,234) (161,966) 287,809 Proceeds from sales of marketable securities 24,438 8,858 61,401 268,058 Proceeds from sales of marketable securities 13,59 40,849 65,040 222,941 Issuance of convertible loan 2,5 4,600 2.22 2.22 Proceeds from life insurance 2,5 3,410 2.3 3,410 2.3 3,410 4.6 4.6 4.6 2.2 1,410 1,410 3,410 <td>Inventories</td> <td>(1,068)</td> <td>(11,992)</td> <td>5,327</td> <td>(80,809)</td>	Inventories	(1,068)	(11,992)	5,327	(80,809)
Deferred revenue and customer advances (7,693) (337) (57,210) (6,233) Retirement plans contributions (1,794) (1,219) (5,492) (5,116) Income taxes 15,762 1,536 (26,921) (29,834) Net cash provided by operating activities 24,878 18,340 585,231 577,923 Cash flows from investing activities 244,381 (34,577) (159,642) (161,249) Purchases of property, plant and equipment (44,336) (34,577) (161,964) (287,409) Proceeds from sales of marketable securities (24,120) (20,234) (161,964) 268,058 Proceeds from maturities of marketable securities 13,595 40,849 85,042 222,941 Issuance of convertible loan - - - 6,060 - Proceeds from life insurance - - 460 - Proceeds from life insurance - - 40,00 - Net cash (used for) provided by investing activities (30,423) 1,694 1,79,645 43,751	Prepayments and other assets	20,881	(46,382)	(43,101)	(140,713)
Retirement plans contributions (1,794) (1,219) (5,492) (5,116) Income taxes 15,762 1,536 (26,921) (29,834) Net cash provided by operating activities 248,780 183,402 585,231 577,923 Cash flows from investing activities 8 8 61,602 (163,249) Purchases of property, plant and equipment (44,336) (34,577) (159,642) (163,249) Purchases of marketable securities 24,438 8,858 61,401 268,058 Proceeds from sales of marketable securities 24,438 8,858 61,401 268,058 Proceeds from life insurance 13,595 40,849 85,042 222,941 Issuance of convertible loan 2 3,410 2 3,410 Net cash (used for) provided by investing activities (30,23) (1,694) (179,65) 3,410 Repurchase of common stock (50,749) (2,082) (397,241) (752,082) Payments of convertible debt principal (35,749) (1,713) (50,249) (66,759)	Accounts payable and other liabilities	42,783	11,911	46,782	(60,507)
Income taxes 15,762 1,536 26,931 29,834 Net cash provided by operating activities 248,780 18,340 585,231 577,923 Cash flows from investing activities 8 585,231 757,923 Purchases of property, plant and equipment (44,336) (34,577) (159,642) (163,249) Purchases of marketable securities 24,438 8,585 61,401 268,058 Proceeds from sale of marketable securities 13,595 40,849 85,042 222,941 Issuance of convertible loan 2 4 56,000 2 Proceeds from life insurance 2 3,410 4 2 Proceeds from life insurance 30,423 10,594 43,75 4 Proceeds from life insurance 30,423 10,694 4,60 4 Net cash (used for) provided by investing activities (30,423) 10,694 1079,645 43,75 Repurchase of common stock (50,74) 20,828 3,741 752,082 Payments related to net settlement of employee stock compensual activities	Deferred revenue and customer advances	(7,693)	(337)	(57,210)	(6,233)
Net cash provided by operating activities 248,780 183,402 585,231 577,923 Cash flows from investing activities: Purchases of property, plant and equipment (44,336) (34,577) (159,642) (163,249) Purchases of marketable securities (24,120) (20,234) (161,906) (287,409) Proceeds from sales of marketable securities 24,438 8,858 61,401 268,058 Proceeds from maturities of marketable securities 13,595 40,849 85,042 222,941 Issuance of convertible loan - - - (5,000) - Proceeds from life insurance - - - 460 - Proceeds from sale of asset - 3,410 - 3,410 Net cash (used for) provided by investing activities (30,423) (1,694) (179,645) 43,751 Cash flows from financing activities (50,749) (2,082) (397,241) (752,082) Payments of common stock (50,749) (2,082) (397,241) (752,082) Payments related to net settlement of employee stock comp	Retirement plans contributions	(1,794)	(1,219)	(5,492)	(5,116)
Cash flows from investing activities: Purchases of property, plant and equipment (44,336) (34,577) (159,642) (163,249) Purchases of property, plant and equipment (24,120) (20,234) (161,906) (287,409) Proceeds from sales of marketable securities 24,438 8,858 61,401 268,058 Proceeds from maturities of marketable securities 13,595 40,849 85,042 222,941 Issuance of convertible loan - - (5,000) - Proceeds from life insurance - 3,410 - 3,410 Proceeds from sale of asset - 3,410 - 3,410 Net cash (used for) provided by investing activities (30,423) (1,694) (179,645) 43,751 Repurchase of common stock (50,749) (2,082) (397,241) (752,082) Payments of convertible debt principal (23,529) (14,754) (50,264) (66,759) Dividend payments (200,100) (17,133) (67,878) (69,711) Payments related to net settlement of employee stock compensation (202)	Income taxes	15,762	1,536	(26,921)	(29,834)
Purchases of property, plant and equipment (44,336) (34,577) (159,642) (163,249) Purchases of marketable securities (24,120) (20,234) (161,906) (287,409) Proceeds from sales of marketable securities 24,438 8,858 61,401 268,058 Proceeds from maturities of marketable securities 13,595 40,849 85,042 222,941 Issuance of convertible loan - - - (50,000) - Proceeds from life insurance - 3,410 - 3,410 Proceeds from sale of asset - 3,410 - 3,410 Net cash (used for) provided by investing activities - 3,410 - 3,410 Repurchase of common stock (50,749) (2,082) (397,241) (752,082 Payments of convertible debt principal (23,529) (14,754) (50,264) (66,759) Dividend payments (201,082) (183) (20,788) (33,170) Issuance of common stock under stock purchase and stock option plans 175 - 34,259 28,733	Net cash provided by operating activities	248,780	183,402	585,231	577,923
Purchases of marketable securities (24,120) (20,234) (161,906) (287,409) Proceeds from sales of marketable securities 24,438 8,858 61,401 268,058 Proceeds from maturities of marketable securities 13,595 40,849 85,042 222,941 Issuance of convertible loan - - - (5,000) - Proceeds from life insurance - 3,410 - 3,410 Net cash (used for) provided by investing activities (30,423) (1,694) (179,645) 43,751 Cash flows from financing activities (50,749) (2,082) (397,241) (752,082) Payments of convertible debt principal (23,529) (14,754) (50,264) (66,759) Dividend payments (16,797) (17,133) (67,878) (69,711) Payments related to net settlement of employee stock compensation awards (202) (183) (20,788) 33,170 Issuance of common stock under stock purchase and stock option plans 175 - 34,259 28,733 Net cash used for financing activities (91,102) <td>Cash flows from investing activities:</td> <td></td> <td></td> <td></td> <td></td>	Cash flows from investing activities:				
Proceeds from sales of marketable securities 24,438 8,858 61,401 268,058 Proceeds from maturities of marketable securities 13,595 40,849 85,042 222,941 Issuance of convertible loan - - - (5,000) - Proceeds from life insurance - 3,410 - 3,410 Proceeds from sale of asset (30,423) (1,694) (179,645) 43,751 Cash flows from financing activities (30,423) (1,694) (179,645) 43,751 Cash flows from financing activities (50,749) (2,082) (397,241) (752,082) Payments of convertible debt principal (23,529) (14,754) (50,264) (66,759) Dividend payments (16,797) (17,133) (67,878) (69,711) Payments related to net settlement of employee stock compensation awards (202) (183) (20,788) (33,170) Issuance of common stock under stock purchase and stock option plans 175 - 34,259 28,733 Net cash used for financing activities (91,102) (34,152) </td <td>Purchases of property, plant and equipment</td> <td>(44,336)</td> <td>(34,577)</td> <td>(159,642)</td> <td>(163,249)</td>	Purchases of property, plant and equipment	(44,336)	(34,577)	(159,642)	(163,249)
Proceeds from maturities of marketable securities 13,595 40,849 85,042 222,941 Issuance of convertible loan - - - (5,000) - Proceeds from life insurance - - - 460 - Proceeds from sale of asset - 3,410 - 3,410 Net cash (used for) provided by investing activities (30,423) (1,694) (179,645) 43,751 Cash flows from financing activities (50,749) (2,082) (397,241) (752,082) Payments of common stock (50,749) (14,754) (50,264) (66,759) Dividend payments (16,797) (17,133) (67,878) (69,711) Payments related to net settlement of employee stock compensation awards (202) (183) (20,788) (33,170) Issuance of common stock under stock purchase and stock option plans 175 - 34,259 28,733 Net cash used for financing activities (91,102) (34,152) (501,912) (892,989) Effects of exchange rate changes on cash and cash equivalents (6,645)	Purchases of marketable securities	(24,120)	(20,234)	(161,906)	(287,409)
Issuance of convertible loan - - (5,000) - Proceeds from life insurance - - 460 - Proceeds from sale of asset - 3,410 - 3,410 Net cash (used for) provided by investing activities (30,423) (1,694) (179,645) 43,751 Cash flows from financing activities: - - 3,410 - 3,410 Payments of common stock (50,749) (2,082) (397,241) (752,082) Payments of convertible debt principal (23,529) (14,754) (50,264) (66,759) Dividend payments (16,997) (17,133) (67,878) (69,711) Payments related to net settlement of employee stock compensation awards (202) (183) (20,788) (33,170) Issuance of common stock under stock purchase and stock option plans 175 - 34,259 28,733 Net cash used for financing activities (91,102) (34,152) (501,912) (892,989) Effects of exchange rate changes on cash and cash equivalents (6,645) (3,529) (876	Proceeds from sales of marketable securities	24,438	8,858	61,401	268,058
Proceeds from life insurance - - 460 - Proceeds from sale of asset - 3,410 - 3,410 Net cash (used for) provided by investing activities (30,423) (1,694) (179,645) 43,751 Cash flows from financing activities: 8 8 6,749 (2,082) (397,241) (752,082) Payments of convertible debt principal (23,529) (14,754) (50,264) (66,759) Dividend payments (16,797) (17,133) (67,878) (69,711) Payments related to net settlement of employee stock compensation awards (202) (183) (20,788) (33,170) Issuance of common stock under stock purchase and stock option plans 175 - 34,259 28,733 Net cash used for financing activities (91,102) (34,152) (501,912) (892,989) Effects of exchange rate changes on cash and cash equivalents (6,645) (3,529) (876) 3,889 Increase (decrease) in cash and cash equivalents (66,645) (70,746) 854,773 1,122,199 Cash and cash equivalents	Proceeds from maturities of marketable securities	13,595	40,849	85,042	222,941
Proceeds from sale of asset - 3,410 - 3,410 Net cash (used for) provided by investing activities (30,423) (1,694) (179,645) 43,751 Cash flows from financing activities: 8 8 50,749 (2,082) (397,241) (752,082) Payments of convertible debt principal (23,529) (14,754) (50,264) (66,759) Dividend payments (16,797) (17,133) (67,878) (69,711) Payments related to net settlement of employee stock compensation awards (202) (183) (20,788) (33,170) Issuance of common stock under stock purchase and stock option plans 175 - 34,259 28,733 Net cash used for financing activities (91,102) (34,152) (501,912) (892,989) Effects of exchange rate changes on cash and cash equivalents (6,645) (3,529) (876) 3,889 Increase (decrease) in cash and cash equivalents 120,610 144,027 (97,202) (267,426) Cash and cash equivalents at beginning of period 636,961 710,746 854,773 1,122,199	Issuance of convertible loan	-	-	(5,000)	_
Net cash (used for) provided by investing activities (30,423) (1,694) (179,645) 43,751 Cash flows from financing activities: (50,749) (2,082) (397,241) (752,082) Payments of convertible debt principal (23,529) (14,754) (50,264) (66,759) Dividend payments (16,797) (17,133) (67,878) (69,711) Payments related to net settlement of employee stock compensation awards (202) (183) (20,788) (33,170) Issuance of common stock under stock purchase and stock option plans 175 - 34,259 28,733 Net cash used for financing activities (91,102) (34,152) (501,912) (892,989) Effects of exchange rate changes on cash and cash equivalents (6,645) (3,529) (876) 3,889 Increase (decrease) in cash and cash equivalents 120,610 144,027 (97,202) (267,426) Cash and cash equivalents at beginning of period 636,961 710,746 854,773 1,122,199 Cash and cash equivalents at end of period \$757,571 854,773 757,571 854,773 <td>Proceeds from life insurance</td> <td>-</td> <td>-</td> <td>460</td> <td>-</td>	Proceeds from life insurance	-	-	460	-
Cash flows from financing activities: Repurchase of common stock (50,749) (2,082) (397,241) (752,082) Payments of convertible debt principal (23,529) (14,754) (50,264) (66,759) Dividend payments (16,797) (17,133) (67,878) (69,711) Payments related to net settlement of employee stock compensation awards (202) (183) (20,788) (33,170) Issuance of common stock under stock purchase and stock option plans 175 - 34,259 28,733 Net cash used for financing activities (91,102) (34,152) (501,912) (892,989) Effects of exchange rate changes on cash and cash equivalents (6,645) (3,529) (876) 3,889 Increase (decrease) in cash and cash equivalents 120,610 144,027 (97,202) (267,426) Cash and cash equivalents at beginning of period 636,961 710,746 854,773 1,122,199 Cash and cash equivalents at end of period \$757,571 \$854,773 \$757,571 \$854,773	Proceeds from sale of asset	-	3,410	-	3,410
Repurchase of common stock (50,749) (2,082) (397,241) (752,082) Payments of convertible debt principal (23,529) (14,754) (50,264) (66,759) Dividend payments (16,797) (17,133) (67,878) (69,711) Payments related to net settlement of employee stock compensation awards (202) (183) (20,788) (33,170) Issuance of common stock under stock purchase and stock option plans 175 - 34,259 28,733 Net cash used for financing activities (91,102) (34,152) (501,912) (892,989) Effects of exchange rate changes on cash and cash equivalents (6,645) (3,529) (876) 3,889 Increase (decrease) in cash and cash equivalents 120,610 144,027 (97,202) (267,426) Cash and cash equivalents at beginning of period 636,961 710,746 854,773 1,122,199 Cash and cash equivalents at end of period \$757,571 \$854,773 757,571 \$854,773	Net cash (used for) provided by investing activities	(30,423)	(1,694)	(179,645)	43,751
Payments of convertible debt principal (23,529) (14,754) (50,264) (66,759) Dividend payments (16,797) (17,133) (67,878) (69,711) Payments related to net settlement of employee stock compensation awards (202) (183) (20,788) (33,170) Issuance of common stock under stock purchase and stock option plans 175 - 34,259 28,733 Net cash used for financing activities (91,102) (34,152) (501,912) (892,989) Effects of exchange rate changes on cash and cash equivalents (6,645) (3,529) (876) 3,889 Increase (decrease) in cash and cash equivalents 120,610 144,027 (97,202) (267,426) Cash and cash equivalents at beginning of period 636,961 710,746 854,773 1,122,199 Cash and cash equivalents at end of period \$757,571 \$854,773 \$757,571 \$854,773	Cash flows from financing activities:				
Payments of convertible debt principal (23,529) (14,754) (50,264) (66,759) Dividend payments (16,797) (17,133) (67,878) (69,711) Payments related to net settlement of employee stock compensation awards (202) (183) (20,788) (33,170) Issuance of common stock under stock purchase and stock option plans 175 - 34,259 28,733 Net cash used for financing activities (91,102) (34,152) (501,912) (892,989) Effects of exchange rate changes on cash and cash equivalents (6,645) (3,529) (876) 3,889 Increase (decrease) in cash and cash equivalents 120,610 144,027 (97,202) (267,426) Cash and cash equivalents at beginning of period 636,961 710,746 854,773 1,122,199 Cash and cash equivalents at end of period \$757,571 \$854,773 \$757,571 \$854,773	Repurchase of common stock	(50,749)	(2,082)	(397,241)	(752,082)
Payments related to net settlement of employee stock compensation awards (202) (183) (20,788) (33,170) Issuance of common stock under stock purchase and stock option plans 175 - 34,259 28,733 Net cash used for financing activities (91,102) (34,152) (501,912) (892,989) Effects of exchange rate changes on cash and cash equivalents (6,645) (3,529) (876) 3,889 Increase (decrease) in cash and cash equivalents 120,610 144,027 (97,202) (267,426) Cash and cash equivalents at beginning of period 636,961 710,746 854,773 1,122,199 Cash and cash equivalents at end of period \$757,571 \$854,773 \$757,571 \$854,773	Payments of convertible debt principal	(23,529)	(14,754)	(50,264)	(66,759)
awards (202) (183) (20,788) (33,170) Issuance of common stock under stock purchase and stock option plans 175 - 34,259 28,733 Net cash used for financing activities (91,102) (34,152) (501,912) (892,989) Effects of exchange rate changes on cash and cash equivalents (6,645) (3,529) (876) 3,889 Increase (decrease) in cash and cash equivalents 120,610 144,027 (97,202) (267,426) Cash and cash equivalents at beginning of period 636,961 710,746 854,773 1,122,199 Cash and cash equivalents at end of period \$757,571 \$854,773 \$757,571 \$854,773	Dividend payments	(16,797)	(17,133)	(67,878)	(69,711)
Issuance of common stock under stock purchase and stock option plans 175 - 34,259 28,733 Net cash used for financing activities (91,102) (34,152) (501,912) (892,989) Effects of exchange rate changes on cash and cash equivalents (6,645) (3,529) (876) 3,889 Increase (decrease) in cash and cash equivalents 120,610 144,027 (97,202) (267,426) Cash and cash equivalents at beginning of period 636,961 710,746 854,773 1,122,199 Cash and cash equivalents at end of period \$757,571 \$854,773 \$757,571 \$854,773	Payments related to net settlement of employee stock compensation	1			
Net cash used for financing activities (91,102) (34,152) (501,912) (892,989) Effects of exchange rate changes on cash and cash equivalents (6,645) (3,529) (876) 3,889 Increase (decrease) in cash and cash equivalents 120,610 144,027 (97,202) (267,426) Cash and cash equivalents at beginning of period 636,961 710,746 854,773 1,122,199 Cash and cash equivalents at end of period \$ 757,571 \$ 854,773 \$ 757,571 \$ 854,773	awards	(202)	(183)	(20,788)	(33,170)
Effects of exchange rate changes on cash and cash equivalents (6,645) (3,529) (876) 3,889 Increase (decrease) in cash and cash equivalents 120,610 144,027 (97,202) (267,426) Cash and cash equivalents at beginning of period 636,961 710,746 854,773 1,122,199 Cash and cash equivalents at end of period \$ 757,571 \$ 854,773 \$ 757,571 \$ 854,773	Issuance of common stock under stock purchase and stock option plans	175	-	34,259	28,733
Effects of exchange rate changes on cash and cash equivalents (6,645) (3,529) (876) 3,889 Increase (decrease) in cash and cash equivalents 120,610 144,027 (97,202) (267,426) Cash and cash equivalents at beginning of period 636,961 710,746 854,773 1,122,199 Cash and cash equivalents at end of period \$ 757,571 \$ 854,773 \$ 757,571 \$ 854,773	Net cash used for financing activities	(91,102)	(34,152)	(501,912)	(892,989)
Increase (decrease) in cash and cash equivalents 120,610 144,027 (97,202) (267,426) Cash and cash equivalents at beginning of period 636,961 710,746 854,773 1,122,199 Cash and cash equivalents at end of period \$ 757,571 \$ 854,773 \$ 757,571 \$ 854,773			(3,529)	(876)	3,889
Cash and cash equivalents at beginning of period 636,961 710,746 854,773 1,122,199 Cash and cash equivalents at end of period \$ 757,571 \$ 854,773 \$ 757,571 \$ 854,773					
Cash and cash equivalents at end of period \$ 757,571 \$ 854,773 \$ 757,571 \$ 854,773	•			, , ,	
					
	•				

GAAP to Non-GAAP Earnings Reconciliation

(In millions, except per share amounts)

					Quarte	r Ended								
	Dec	cember					December							
	31,		% of Net	Oct	ober 1,	% of Net		31,	% of Net					
	2	2023	Revenues	2023		Revenues	2022		Revenues					
Net revenues	\$	670.6		\$	703.7		\$	731.8						
Gross profit GAAP and non-GAAP		379.5	56.6 %		398.3	56.6 %		420.4	57.4 %					
Income from operations - GAAP		124.3	18.5 %		144.0	20.5 %		166.6	22.8 %					
Restructuring and other (1)		6.0	0.9 %		6.9	1.0 %		(2.4)	-0.3 %					
Acquired intangible assets amortization		4.7	0.7 %		4.7	0.7 %		4.7	0.6 %					
Income from operations - non-GAAP	\$	135.0	20.1 %	\$	155.6	22.1 %	\$	168.9	23.1 %					
	NT.	4 T			NI - 4 T-				NI-4 To a comp					

				Net I	ncome			Net I	ncome			Net I	ncome
				per C	ommon			per C	ommon			per C	ommon
				Sh	nare			Sł	nare			Sh	are
	D	ecembe				Octobe				Decembe			
		r 31,	% of Net			r 1,	% of Net			r 31,	% of Net		
		2023	Revenues	Basic	Diluted	2023	Revenues	Basic	Diluted	2022	Revenues	Basic	Diluted
Net income - GAAP	\$	117.1	17.5%	\$ 0.77	\$ 0.72	\$ 128.1	18.2%	\$ 0.83	\$ 0.78	\$ 172.3	23.5%	\$ 1.11	\$ 1.04
Restructuring and	d												
other (1)		6.0	0.9%	0.04	0.04	6.9	1.0%	0.04	0.04	(2.4)	-0.3%	(0.02)	(0.01)



rension mark-to-									
market adjustment									
(2)	2.6	0.4% 0.02	0.02	0.1	0.0% 0.00	0.00	(25.6)	-3.5% (0.16)	(0.15)
Gain on foreign									
exchange option	(7.5)	-1.1% (0.05) (0.05)	-		-	-		-
Exclude discrete									
tax adjustments	3.3	0.5% 0.02	0.02	(4.8)	-0.7% (0.03)	(0.03)	(2.8)	-0.4% (0.02)	(0.02)
Non-GAAP tax									
adjustments	1.0	0.1% 0.01	0.01	(3.5)	-0.5% (0.02)	(0.02)	4.5	0.6% 0.03	0.03
Convertible share									
adjustment (3)									0.01
Net income - non-									
GAAP \$	127.2	19.0% \$ 0.83	\$ 0.79	\$ 131.5	18.7% \$ 0.86	\$ 0.80 \$	150.8	20.6% \$ 0.97	0.92
GAAP and non-									
GAAP weighted									
average common									
shares - basic	152.8			153.8			155.8		
GAAP weighted									
average common									
shares - diluted	162.1			164.1			165.5		
Exclude dilutive									
shares related to									
convertible note									
transaction	(0.2)			(0.6)			(1.2)		
Non-GAAP weighted									
average common									
shares - diluted	161.9			163.4		_	164.3		
(1) Restructuring and oth	er consists	of:							

			Quarte	r Ended		
	Decembe	December 31,			Decen	ber 31,
	2023		20	023	20)22
Acquisition and divestiture related expenses	\$	3.1	\$	-	\$	_
Employee severance		2.9		4.7		0.8
Contract termination		-		1.5		-
Gain on sale of asset		-		-		(3.4)
Other		-		0.6		0.3
	\$	6.0	\$	6.9	\$	(2.4)

- (2) For the quarters ended December 31, 2023, October 1, 2023 and December 31, 2022 adjustment to exclude actuarial (gain) loss recognized under GAAP in accordance with Teradyne's mark-to-market pension accounting.
- (3) For the quarter ended December 31, 2022, the non-GAAP diluted EPS calculation adds back \$0.2 million of convertible debt interest expense to non-GAAP net income. For the quarters ended December 31, 2023, October 1, 2023, and December 31, 2022, non-GAAP weighted average diluted common shares include 8.6 million, 9.2 million and 7.9 million shares, respectively, from the convertible note hedge transaction.

Tweive Months Ended						
December 31,		% of Net	December 31,		% of Net	
	2023	Revenues		2022	Revenues	
\$	2,676.3		\$	3,155.0		
	1,536.7	57.4 %		1,867.2	59.2 %	
	501.1	18.7 %		831.9	26.4 %	
	21.3	0.8 %		17.2	0.5 %	
	19.0	0.7 %		19.3	0.6 %	
	5.9	0.2 %		-	-	
\$	547.3	20.4 %	\$	868.4	27.5 %	
		\$ 2,676.3 1,536.7 501.1 21.3 19.0 5.9	December 31, % of Net 2023 Revenues \$ 2,676.3 57.4 % 1,536.7 57.4 % 501.1 18.7 % 21.3 0.8 % 19.0 0.7 % 5.9 0.2 %	December 31, % of Net December 32 2023 Revenues \$ 2,676.3 \$ 1,536.7 57.4 % 501.1 18.7 % 21.3 0.8 % 19.0 0.7 % 5.9 0.2 %	December 31, % of Net Revenues December 31, \$ 2,676.3 \$ 3,155.0 \$ 1,536.7 57.4 % 1,867.2 \$ 501.1 18.7 % 831.9 21.3 0.8 % 17.2 19.0 0.7 % 19.3 5.9 0.2 % -	

Net Income per Common Share per Common Share

Net Income



Net income - GAAP	\$	448.8	10.8%	\$	2.91	\$	2.13	\$	/13.3	22./%	\$	4.52	\$	4.22
Restructuring and other (1)		21.3	0.8%		0.14		0.13		17.2	0.5%		0.11		0.10
Acquired intangible assets amortization		19.0	0.7%		0.12		0.12		19.3	0.6%		0.12		0.11
Equity modification charge (2)		5.9	0.2%		0.04		0.04		-	-		-		_
Pension mark-to-market adjustment (3)		2.7	0.1%		0.02		0.02		(25.6)	-0.8%		(0.16)		(0.15)
Gain on foreign exchange option		(7.5)	-0.3%		(0.05)		(0.05)		-	-		-		_
Exclude discrete tax adjustments		(3.4)	-0.1%		(0.02)		(0.02)		(12.1)	-0.4%		(80.0)		(0.07)
Non-GAAP tax adjustments		(7.7)	-0.3%		(0.05)		(0.05)		(1.4)	0.0%		(0.01)		(0.01)
Convertible share adjustment (4)		-	-		-		0.01		-	-		-		0.05
Net income - non-GAAP	\$	479.1	17.9%	\$	3.10	\$	2.93	\$	712.9	22.6%	\$	4.50	\$	4.25
GAAP and non-GAAP weighted average	e													
common shares - basic		154.3							158.4					
GAAP weighted average common shares	-													
diluted		164.3							169.7					
Exclude dilutive shares from convertible	e													
note		(0.6)							(1.8)					
Non-GAAP weighted average commo	n													
shares - diluted		163.7							167.9					
(1) Pastmaturing and other consists of														

(1) Restructuring and	other consists of	of:
-----------------------	-------------------	-----

I weive life	Twelve Months Ended				
December 31,	December 31,				
2023	2022				
Employee severance \$ 14.8	\$	2.9			
Acquisition and divestiture related expenses 3.1		-			
Contract termination 1.5		-			
Litigation settlement		14.7			
Gain on sale of asset		(3.4)			
Other 1.9		3.0			
\$ 21.3	\$	17.2			

- (2) For the twelve months ended December 31, 2023, selling and administrative expenses include an equity charge of \$5.9 million for the modification of Teradyne's retired CEO's outstanding equity awards in connection with his February 1, 2023 retirement.
- (3) For the twelve months ended December 31, 2023 and December 31, 2022, adjustment to exclude actuarial (gain) loss recognized under GAAP in accordance with Teradyne's mark-to-market pension accounting.
- (4) For the twelve months ended December 31, 2023 and December 31, 2022, the non-GAAP diluted EPS calculation adds back \$0.2 million and \$1.0 million, respectively, of convertible debt interest expense to non-GAAP net income. For the twelve months ended December 31, 2023 and December 31, 2022, non-GAAP weighted average diluted common shares include 8.9 million and 8.8 million shares, respectively, related to the convertible debt hedge transaction.

GAAP to Non-GAAP Reconciliation of First Quarter 2024 guidance:

GAAP and non-GAAP first quarter revenue guidance:	\$540 million	to	\$590 million
GAAP net income per diluted share	0.19	\$	0.35
Exclude acquired intangible assets amortization	0.03		0.03
Exclude restructuring and other charges	0.01		0.01
Non-GAAP tax adjustments	(0.01)	·	(0.01)
Non-GAAP net income per diluted share	0.22	\$	0.38

For press releases and other information of interest to investors, please visit Teradyne's homepage at http://www.teradyne.com.

Contact:Teradyne, Inc.

Andy Blanchard 978-370-2425 Vice President of Corporate Relations

SOURCE: Teradyne, Inc.

Topic: Earnings



Press release distribution that gets you the engagement and visibility your brand deserves.

CONTACT US TODAY!

Our industry-leading global news distribution is the most effective platform to reach your target audience.

ACCESSWIRE °		ABOUT	RESOURCES	CONNECT TODAY			
		WHO WE ARE	FAQ	SALES			
		WHO WE SERVE	COMPANY SPOTLIGHT	EDITORIAL			
[facebook.com]	[twitter.com]	CONTACT	SAMPLE PRESS RELEASE	CONTENT LICENSING			
	[linkedin.com]	PRODUCTS	PRESS RELEASE TEMPLATE	JOIN OUR NEWSLETTER			
	[mikedin.com]	PRODUCTS PROGRAMMENT OF THE PROTECTION OF THE PROPERTY OF THE PROPERTY OF THE PROTECTION OF THE PROPERTY OF T	BLOG	[info.accesswire.com]			
		PRESS RELEASE DISTRIBUTION	CUCTOMED DEVIEWS	866-694-3099			
		PRESS RELEASE OPTIMIZER	CUSTOMER REVIEWS				
		ONLINE MEDIA ROOM	LOGIN				
		IR WEBSITES					
		WEBCASTING					
		NEWSROOM					